Atea Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations. Earnings and Valuation This table compares Akebia […]

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Analyst Recommendations This is a breakdown of […]

Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends. Earnings & Valuation This table compares Akebia […]

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Atea Pharmaceuticals in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst R. Ruiz anticipates that the company will earn ($0.66) per share for the quarter. The consensus estimate […]